EEM vs XBI
iShares MSCI Emerging Markets ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.72% for EEM.
- • EEM pays a higher dividend yield (1.83%).
Side-by-side metrics
| Metric | EEM | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.72% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.83% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $28.25B | $10.92B |
YTD return | 12.11% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.07 | 1.01 |
P/E ratio | 14.62 | — |
Last price | $62.27 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
EEM top holdings
| 2330.TW | Taiwan Semiconductor Manufacturing Co Ltd | 15.84% |
| 005930.KQ | Samsung Electronics Co Ltd | 6.98% |
| 000660.KQ | SK hynix Inc | 5.19% |
| 0700.HK | Tencent Holdings Ltd | 2.65% |
| 9988.HK | Alibaba Group Holding Ltd Ordinary Shares | 1.84% |
| 2454.TW | MediaTek Inc | 1.53% |
| 00939 | China Construction Bank Corp Class H | 0.97% |
| 2317.TW | Hon Hai Precision Industry Co Ltd | 0.82% |
| HDFCBANK.NS | HDFC Bank Ltd | 0.74% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About EEM
EEM (iShares MSCI Emerging Markets ETF) is Liquid emerging-market equities. Managed by iShares, the fund carries $28.2B in assets under management, an expense ratio of 0.72%, a dividend yield of 1.83%. Its largest holding is Taiwan Semiconductor Manufacturing Co Ltd (2330.TW), which represents 15.8% of the portfolio. Real Estate is the fund's largest sector exposure at 1.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.